Baker BROS. Advisors LP purchased a new position in shares of Mast Therapeutics Inc (NASDAQ:MSTX) during the third quarter, Holdings Channel reports. The firm purchased 8,584,051 shares of the company’s stock, valued at approximately $944,000. Baker BROS. Advisors LP owned 4.05% of Mast Therapeutics as of its most recent SEC filing.
Separately, BlackRock Institutional Trust Company N.A. raised its position in Mast Therapeutics by 618.9% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,719,932 shares of the company’s stock worth $189,000 after buying an additional 1,480,698 shares during the period.
Shares of Mast Therapeutics Inc (NASDAQ:MSTX) traded up 0.000% during trading on Tuesday, hitting $0.132. 5,579,840 shares of the company’s stock were exchanged. Mast Therapeutics Inc has a 1-year low of $0.07 and a 1-year high of $0.71. The stock’s market cap is $31.45 million. The stock’s 50-day moving average price is $0.12 and its 200-day moving average price is $0.22.
A number of equities analysts have weighed in on the stock. Canaccord Genuity reaffirmed a “buy” rating on shares of Mast Therapeutics in a research note on Thursday, January 19th. Zacks Investment Research downgraded shares of Mast Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 4th.
Mast Therapeutics Company Profile
Mast Therapeutics, Inc is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options.
Want to see what other hedge funds are holding MSTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mast Therapeutics Inc (NASDAQ:MSTX).